AU2852699A - Pharmaceutical composition containing a cysteine protease inhibitor for prophylaxis and therapy of brain tissue impairment - Google Patents

Pharmaceutical composition containing a cysteine protease inhibitor for prophylaxis and therapy of brain tissue impairment Download PDF

Info

Publication number
AU2852699A
AU2852699A AU28526/99A AU2852699A AU2852699A AU 2852699 A AU2852699 A AU 2852699A AU 28526/99 A AU28526/99 A AU 28526/99A AU 2852699 A AU2852699 A AU 2852699A AU 2852699 A AU2852699 A AU 2852699A
Authority
AU
Australia
Prior art keywords
formula
group
carbon atoms
pharmaceutical composition
brain tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU28526/99A
Other languages
English (en)
Inventor
Mitsuyoshi Azuma
Jun Inoue
Yuji Sakamoto
Yukuo Yoshida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senju Pharmaceutical Co Ltd
Original Assignee
Senju Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharmaceutical Co Ltd filed Critical Senju Pharmaceutical Co Ltd
Publication of AU2852699A publication Critical patent/AU2852699A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Peptides Or Proteins (AREA)
AU28526/99A 1998-03-20 1999-03-17 Pharmaceutical composition containing a cysteine protease inhibitor for prophylaxis and therapy of brain tissue impairment Abandoned AU2852699A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP10-72280 1998-03-20
JP7228098 1998-03-20
PCT/JP1999/001335 WO1999048522A1 (en) 1998-03-20 1999-03-17 Pharmaceutical composition containing a cysteine protease inhibitor for prophylaxis and therapy of brain tissue impairment

Publications (1)

Publication Number Publication Date
AU2852699A true AU2852699A (en) 1999-10-18

Family

ID=13484725

Family Applications (1)

Application Number Title Priority Date Filing Date
AU28526/99A Abandoned AU2852699A (en) 1998-03-20 1999-03-17 Pharmaceutical composition containing a cysteine protease inhibitor for prophylaxis and therapy of brain tissue impairment

Country Status (19)

Country Link
US (1) US6342531B1 (enExample)
EP (1) EP1064021B1 (enExample)
JP (1) JP2002507579A (enExample)
KR (1) KR20010041967A (enExample)
CN (1) CN1301173A (enExample)
AR (1) AR018784A1 (enExample)
AT (1) ATE275420T1 (enExample)
AU (1) AU2852699A (enExample)
BR (1) BR9908948A (enExample)
CA (1) CA2324566A1 (enExample)
DE (1) DE69919995T2 (enExample)
ES (1) ES2224613T3 (enExample)
HU (1) HUP0101428A2 (enExample)
ID (1) ID27507A (enExample)
MX (1) MXPA00009188A (enExample)
MY (1) MY133063A (enExample)
NO (1) NO20004679L (enExample)
PL (1) PL342970A1 (enExample)
WO (1) WO1999048522A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7766300A (en) * 1999-10-07 2001-05-10 Novaneuron Inc. Gene necessary for striatal function, uses thereof, and compounds for modulatingsame
JPWO2002034252A1 (ja) 2000-10-26 2004-03-04 千寿製薬株式会社 ジペプチジルアルデヒド誘導体含有医薬組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992011850A2 (en) 1990-12-28 1992-07-23 Cortex Pharmaceuticals, Inc. Use of calpain inhibitors in the inhibition and treatment of neurodegeneration
ATE239698T1 (de) 1995-10-25 2003-05-15 Senju Pharma Co Angiogenese hemmer

Also Published As

Publication number Publication date
PL342970A1 (en) 2001-07-16
MXPA00009188A (es) 2002-04-24
EP1064021B1 (en) 2004-09-08
ES2224613T3 (es) 2005-03-01
ID27507A (id) 2001-04-12
KR20010041967A (ko) 2001-05-25
NO20004679D0 (no) 2000-09-19
ATE275420T1 (de) 2004-09-15
DE69919995D1 (de) 2004-10-14
DE69919995T2 (de) 2005-09-22
US6342531B1 (en) 2002-01-29
AR018784A1 (es) 2001-12-12
BR9908948A (pt) 2000-11-21
MY133063A (en) 2007-10-31
WO1999048522A1 (en) 1999-09-30
JP2002507579A (ja) 2002-03-12
NO20004679L (no) 2000-10-26
CA2324566A1 (en) 1999-09-30
EP1064021A1 (en) 2001-01-03
CN1301173A (zh) 2001-06-27
HUP0101428A2 (hu) 2001-09-28

Similar Documents

Publication Publication Date Title
KR100508393B1 (ko) 신경변성질환 치료약
AU751701B2 (en) Ace inhibitor-MMP inhibitor combinations
MXPA99001974A (es) Metodo para tratar y prevenir fallas cardiacas y dilatacion ventricular.
HRP980322A2 (en) COMPOSITIONS FOR TREATING AND PREVENTING ARTERIAL THROMBOSIS AND USE OF A FACTOR Xa INHIBITOR ON ITS OWN AND/OR COMBINED WITH A PLATELET ANTIAGGREGATING AGENT
US7276514B2 (en) Pyrroloquinoline quinone drugs for treatment of cardiac injury and methods of use thereof
JP2002505297A (ja) 眼底組織細胞障害による疾患の予防および治療用医薬組成物
BE905198A (nl) Farmaceutische preparaten met vaatverwijdende en anti-anoxische werking.
JP4213339B2 (ja) 発作を治療するのに有用なアミノ酸誘導体
CA1228818A (en) Treatment of seizure disorders and pharmaceutical compositions useful therein
EP1064021B1 (en) Use of cysteinprotease inhibitors for the manufacture of a medicament for prevention and treatment of brain tissue impairment due to hypertensive encephalopathy or encephalothlipsis.
KR20230116002A (ko) 항혈전제로서 시클로스포린 유사체의 용도
US20120122873A1 (en) Amino derivatives of dihydro-1,3,5-triazine used in the treatment of ischemia and/or reperfusion related diseases
CN121926911A (zh) N,n-双-2-巯基乙基间苯二甲酰胺的新用途
JP2007536256A (ja) 心臓損傷の処置のためのピロロキノリンキノン薬およびその使用方法
CA2285350A1 (en) Treatment for pulmonary fibrosis
JP2665564B2 (ja) 細胞防護剤
US20040180895A1 (en) Use of a pyridazinone derivative
US5869526A (en) δ-(S-methylisothioureido)-L-norvaline therapeutic for cerebrovascular diseases having nitric oxide synthase inhibiting factor
KR101016593B1 (ko) 환식 반아세탈 유도체 및 이의 용도
JP2004250447A (ja) 心血管病の治療又は予防の為の医薬組成物
JP2008056565A (ja) 遅発性神経細胞死を防御または救済するための薬剤および方法
JP2004315469A (ja) シトルリン血症治療剤
CA2213507A1 (en) Pharmaceutical composition for treating transient ischemic attack
JPWO1992001468A1 (ja) エンドセリン変換酵素阻害剤または血管攣縮治療剤
MXPA00006353A (en) Remedy for neurodegenerative diseases___________________________

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted